Cingulate increases ATM offering capacity by $2.86M; receives European patent for ADHD drug CTx-1301

Cingulate Inc.

Increased maximum aggregate offering of common stock under Sales Agreement from $8.47M to $11.33M; filed prospectus supplement for $2.86M in additional shares.
Previously sold $8.47M of common stock under the Sales Agreement with H.C. Wainwright & Co.
European patent (EP 3261625) granted for lead asset CTx-1301 (dexmethylphenidate) for ADHD on August 14, 2024.
Patent covers up to 30 European territories, including the United Kingdom.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.